Whalesbook
Aakhir revenue badh kar bhi profit kyun gira?
Is baar Dr Lal PathLabs (DLPL) ka revenue toh badha hai, almost 16.6% upar gaya ₹702.7 crore tak. Yeh growth mostly sample aur patient volumes mein 13% ke rise se aayi hai, inke expanding network, Swasthfit offering aur Suburban business ki wajah se.
Par yeh khushi zyada der nahi chali kyunki net profit 15.2% kam hokar ₹131.3 crore ho gaya. Iska reason hai EBITDA margins ka 28% se ghata kar 26.6% ho jaana. Lagta hai operational costs, jaise collection centers ko diye jaane wale fees, revenue growth se zyada badh gaye hain.
Is khabar ke baad, DLPL ka share NSE par 1.7% neeche band hua, ₹1,374 pe. Shares toh saal aur pichhle 6 mahine mein bhi gire hain, jise dekh kar investors ko profit kam hone ki chinta ho rahi hai, bhale hi revenue badh raha ho.
Valuation aur Market ka Kya Scene Hai?
Currently, DLPL ka valuation (Price-to-Earnings ratio) around 44.5x hai. Yeh numbers agar compare karein toh Krsnaa Diagnostics 23.8x pe hai, toh Metropolis Healthcare 58.3x se 71.6x ke beech mein hai. Toh DLPL ka P/E Metropolis se kam hai par Krsnaa se kaafi zyada, matlab market inke future growth ko lekar kaafi optimistic hai.
Waise bhi, Indian diagnostics market toh future mein kaafi grow hone wala hai, around 11.23% CAGR se 2034 tak USD 28.53 billion tak pahunch sakta hai. Health awareness badh rahi hai, tech aa rahi hai, home collection services chal rahi hain.
Company ki Strength aur Growth Drivers
Dr Lal Pathlabs toh market mein leader hai, market cap lagbhag ₹22,900 crore hai. Poore India mein network hai aur kaafi time se business mein hain. Company apna network aur test menu expand kar rahi hai, jaise ki genomic profiles. Mumbai mein presence strong karne ke liye Shahbazkers Diagnostic Centre ko bhi acquire kiya hai. Suburban Diagnostics ko formally dissolve bhi kiya hai business streamline karne ke liye.
Management ko FY27 mein mid-teens revenue growth ki umeed hai. Swasthfit se 27% revenue aa raha hai FY26 mein, aur Suburban business bhi improve ho raha hai. Analysts ne FY27/28 revenue estimates ko 3% badhaya hai. Sector domestic demand se strong hai, aur log quality ke liye organised players ko prefer karte hain.
Margin Pressure Aur High Valuation Ki Chinta
Ab baat karein DLPL ke 44.5x P/E ki, toh yeh thoda high lag raha hai jab profit aur margins kam ho rahe hain. Revenue 16.6% badha, par profit 15.2% gira, matlab operational costs control mein nahi hain. Krsnaa Diagnostics jaise competitors toh bahut kam P/E pe trade kar rahe hain.
Analyst Log Kya Keh Rahe Hain?
Analysts abhi bhi positive hain, mostly 'Buy' rating de rahe hain. Average 12-month target price ₹1,720 hai, matlab current price se 25% se zyada upside dikh raha hai. Emkay Global Financial ne ₹1,740 ka target rakha hai, Kotak Securities ne ₹1,760, aur Citi ne ₹1,650. Sector ki stability aur domestic demand toh achhi hai, par agar margin pressure bana raha toh high valuation ko justify karna mushkil ho jayega.